Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

So we started with the phase III trial,” Prof Toh said. Unlike the well-known chimeric antigen receptor (Car) T-cell, which ...

2seventy Bio focuses on pioneering cell and gene therapies. Its lead product, Abecma, is a chimeric antigen receptor (CAR) ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

European patients had previously seen an improvement in their lupus symptoms after the therapy was tested in an earlier trial ...

A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

1 Obe-cel is a chimeric antigen receptor (CAR) T-cell therapy that is the first approved by the FDA without a requirement for ...